These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 11, 2017
ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for prostate cancer, today reported financial results for the...
-
Nov 22, 2017
TSX VENTURE LISTING EXPECTED TO IMPROVE OPERATING EFFICIENCY, LOWER COSTS AND PROVIDE ENHANCED FINANCING FLEXIBILITY COMPANY'S SHARES TO REMAIN LISTED ON NASDAQ CAPITAL MARKET VANCOUVER and...
-
Sep 11, 2017
Updated data from ongoing Phase 1 trial presented at ESMO Confirmed EPI-506 is well-tolerated with a favorable safety profile Long-term stable disease and PSA reductions at higher dose levels in...
-
Sep 7, 2017
ESSA Pharma Inc. (TSX: EPI; NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate...
-
Sep 1, 2017
ESSA Pharma Inc. (TSX: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical stage company focused on the development of small molecule drugs for the treatment of cancer, today announced that...
